MRK Sinks After Abandoning COVID-19 Vaccine Program

The equity has had a volatile run on the charts during the past 12 months

Digital Content Manager
Jan 25, 2021 at 9:47 AM
    facebook twitter linkedin


    The shares of Merck & Co., Inc. (NYSE:MRK) are off 1.2% to trade at $80 this morning, following news that the pharmaceutical company is ending its COVID-19 vaccine development program. The firm said both of its vaccines generated inferior immune responses, and plans to shift its focus to pandemic research on treatment, adding that its expects initial data on its experimental oral antiviral to be due out by the end of March. 

    The past 12 months have been quite choppy for MRK, though its most recent major pullback in December staged a bounce off the $78 mark, before running into trouble at the frequently resistant $86 level. Shares have once again pulled back to test their footing at the 200-day moving average, which has kept the security afloat numerous times during the past three months. 

    Despite its volatility, analysts are optimistic on the stock. Of the 13 in coverage, 10 say "strong buy." Plus, the 12-month consensus price target of $96.60 is a 20.8% premium to last night's close. 

    Option traders have taken a sunny outlook on MRK, too. This is per the equity's 10-day call/put volume ratio of 4.57 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), which stands higher than 78% of all other readings from the past year. This means long calls are being picked up at a relatively quicker-than-usual clip. 

     

     

    Stop leaving money on the table with the same old broken options trading approach...

    There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

     
    Best stocks for October and worst stocks for October
     


     


     
    Special Offers from Schaeffer's Trading Partners